Adicet Bio to Participate in a Fireside Chat at the 45th Annual Canaccord Genuity Growth Conference

Audio By Carbonatix

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Aug 5, 2025--

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 45th Annual Canaccord Genuity Growth Conference being held from August 12-14, 2025 in Boston.

Details of the event are as follows:
Date: Tuesday, August 12, 2025
Time: 1:30 p.m. ET

The live audio webcast can be accessed on the Investors section of Adicet Bio’s website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at https://www.adicetbio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250805508642/en/

CONTACT: Adicet Bio, Inc.

Investor and Media ContactsAnne Bowdidge

[email protected] Belnap

Precision AQ

212-362-1200

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH SCIENCE RESEARCH CLINICAL TRIALS

SOURCE: Adicet Bio, Inc.

Copyright Business Wire 2025.

PUB: 08/05/2025 07:00 AM/DISC: 08/05/2025 07:00 AM

http://www.businesswire.com/news/home/20250805508642/en